Prospective assessment of the Hong Kong Hospital Authority universal Down syndrome screening programme

Hong Kong Medical Journal

Volumn 19, Issue 2, 2013, Pages 101-108

  Sahota, Daljit S ^a   Leung, W C ^b   Chan, W P ^c   To, William W K ^d   Lau, Elizabeth T ^e   Leung, T Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c PRINCESS MARGARET HOSPITAL   (Hong Kong)

^d UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Down syndrome; First trimester screening; Nuchal translucency; Quality control; Second trimester screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PROTEIN A;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GENETIC RISK; GESTATIONAL AGE; HONG KONG; HORMONE BLOOD LEVEL; HOSPITAL DEPARTMENT; HUMAN; INVASIVE PROCEDURE; LIVE BIRTH; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY OUTCOME; PRENATAL SCREENING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; TRISOMY 21; UNIVERSAL DOWN SYNDROME SCREENING PROGRAM;

DOWN SYNDROME; FIRST TRIMESTER SCREENING; NUCHAL TRANSLUCENCY; QUALITY CONTROL; SECOND TRIMESTER SCREENING;

ADOLESCENT; ADULT; AMNIOCENTESIS; COHORT STUDIES; DOWN SYNDROME; FEMALE; HONG KONG; HUMANS; MASS SCREENING; MATERNAL AGE; MATERNAL SERUM SCREENING TESTS; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; RISK ASSESSMENT; ULTRASONOGRAPHY, PRENATAL; YOUNG ADULT;

EID: 84876045622     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Leung TY, Chan LW, Leung TN, et al. First-trimester combined screening for trisomy 21 in a predominantly Chinese population. Ultrasound Obstet Gynecol 2007;29:14-7.
2. Leung TY, Chan LW, Law LW, et al. First trimester combined screening for trisomy 21 in Hong Kong: outcome of the first 10, 000 cases. J Matern Fetal Neonatal Med 2009;22:300-4.
3. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
4. Sahota DS, Leung TY, Chan LW, et al. Comparison of first trimester contingent screening strategies for Down syndrome. Ultrasound Obstet Gynecol 2010;35:286-91.
5. Sahota DS, Leung TY, Fung TY, Chan LW, Law LW, Lau TK. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 2009;33:387-93.
6. Sahota DS, Leung TY, Leung TN, Chan OK, Lau TK. Fetal crown-rump length and estimation of gestational age in an ethnic Chinese population. Ultrasound Obstet Gynecol 2009;33:157-60.
7. Sahota DS, Chen M, Leung TY, et al. Assessment of sonographer nuchal translucency measurement performance-central tendency and dispersion. J Matern Fetal Neonatal Med 2011;24:812-6.
8. Sahota DS, Leung WC, To WK, Chan WP, Lau TK, Leung TY. Quality assurance of nuchal translucency for prenatal fetal Down syndrome screening. J Matern Fetal Neonatal Med 2012;25:1039-43.
9. Lau TK, Chan MK, Lo PS, et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test-early experience. J Matern Fetal Neonatal Med 2012;25:1856-9.
10. Christiansen M, Larsen SO. Precision of risk in multidimensional likelihood ratio based screening with first trimester screening for Down's syndrome as a special case. J Med Screen 2001;8:61-4.
11. Territory-wide O&G Audit Report 2004. Available from: http://hkcog.obg.cuhk.edu.hk/public/docs/audit/audit_og_report_2004.pdf. Accessed 1 Feb 2009.
12. Newnham JP, Sahota DS, Zhang CY, et al. Preterm birth rates in Chinese women in China, Hong Kong and Australia - the price of Westernisation. Aust N Z J Obstet Gynaecol 2011;51:426-31.
13. Cuckle H. Monitoring the quality control of nuchal translucency. Clin Lab Med 2010;30:593-604.
14. Down's Syndrome Quality Assurance Support Service (DQASS). QA of the MOM letter. NHS website: http://fetalanomaly.screening.nhs.uk/getdata.php?id=10707. Accessed 1 Feb 2009.
15. Office for National Statistics. Birth statistics. Review of the Registrar General on births and patterns of family building in England and Wales, 2000-2002. Series FM1, Nos 29-31. London: Stationery Office; 2000-2002.
16. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009;34:14-8.
17. United Kingdom National Screening Committee (UKNSC). Screening for Down's syndrome: UK NSC Policy recommendations 2011-2014 Model of Best Practice. NHS website: http://fetalanomaly.screening.nhs.uk/getdata.php?id=11393. Accessed 1 Mar 2012.
18. Cuckle H, Maymon R. Down syndrome risk calculation for a twin fetus taking account of the nuchal translucency in the co-twin. Prenat Diagn 2010;30:827-33.
19. Leung TY, Sahota D, Chan LW, Law LW, Fung TY, Lau TK. Fetal nasal bone status in Chinese women undergoing first-trimester screening for trisomy 21. Am J Obstet Gynecol 2008:199:521.e1-5.
20. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:e1-5.
21. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401.
22. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
23. Chitty LS, Hill M, White H, Wright D, Morris S. Noninvasive prenatal testing for aneuploidy-ready for prime time? Am J Obstet Gynecol 2012;206:269-75.
24. Benn P, Cuckle H, Pergament E. Non-invasive prenatal diagnosis for Down syndrome: the paradigm will shift, but slowly. Ultrasound Obstet Gynecol 2012;39:127-30.
25. Benn P, Borrell A, Cuckle H, et al. Prenatal detection of Down syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenatal Diagn 2012;32:1-2.
26. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
27. Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 2011;31:135-41.
28. Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011;29:148-54.
29. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010;30:293-308.
30. Chan YM, Sahota DS, Leung TY, Choy KW, Chan OK, Lau TK. Chinese women's preferences for prenatal diagnostic procedure and their willingness to trade between procedures. Prenat Diagn 2009;29:1270-6.
31. Lam YH, Ghosh A, Tang MH, et al. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. Prenat Diagn 1998;18:585-9.